Rexin G
Star0
Identification
- Generic Name
- Rexin G
- DrugBank Accession Number
- DB16450
- Background
Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Gene Therapies
Other gene therapies - Synonyms
- DeltaRex-G
- DeltaRex-G Retroviral Vector Encoding a Cyclin G1 Inhibitor
- Mx-dnG1 retroviral vector
- retroviral expression vector bearing anti-cyclin G1 gene construct
- Rexin-G
- External IDs
- Mx-dnG1
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Rexin G is a non-pathogenic entity that mimics SARS-COV2 by binding to receptors to gain entry into human cells. It is being investigated for preventing SARSCOV-2 viral entry, and also acts as an inhibitor of the cyclin G1 pathway.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 1023923-93-4
References
- General References
- External Links
- Wikipedia
- Rexin_G
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1, 2 Withdrawn Treatment Acute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19) / Cytokine Storm 1 Not Available Available Not Available Breast Carcinoma / Chondrosarcomas / Chordomas / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Osteosarcoma / Pancreatic Cancer / Sarcomas / Soft Tissue Sarcoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at January 21, 2021 01:43 / Updated at February 13, 2021 10:53